Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Philippe Moreau, Maria Victoria Mateos, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A. Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A. Keith Stewart
Dive into the research topics of 'Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study'. Together they form a unique fingerprint.